Top

Published in:

01-02-2012 | PRECLINICAL STUDIES

3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression

Authors: Gleice da Graça Rocha, Marisol Simões, Rodrigo Rodrigues Oliveira, Maria Auxiliadora Coelho Kaplan, Cerli Rocha Gattass

Published in: Investigational New Drugs | Issue 1/2012

Summary

Chronic Myeloid Leukemia (CML) is a potentially fatal stem-cell cancer. P-glycoprotein (P-gp/ABCB1) activity has been described as a relevant factor in the chemotherapeutic failure and correlated to a poor prognosis in these malignancies. In the present study, we investigated the mechanism of the antineoplastic activity of 3β-acetyl tormentic acid (3ATA), a triterpene isolated from C. lyratiloba, on Lucena-1, an MDR leukemia cell line, that overexpressed P-gp/ABCB1. Results showing that this triterpene induced DNA-fragmentation, activation of caspase-3 and cytochrome c release indicated that its activity is mediated by the activation of the intrinsic pathway of apoptosis. Interestingly, this triterpene did not interfere with P-gp/ABCB1 expression or activity, indicating that induction of death is not mediated by any effect on this protein. Moreover, the results show that none of the others triterpenes from C. lyratiloba were able to modulate the activity of P-gp/ABCB1. Together these results suggest 3ATA and the other triterpenes as a promising material for the development of anti-neoplastic drugs for leukemia and other tumors independent of P-gp/ABCB1 activity or expression.

Sessions J (2007) Chronic myeloid leukemia in 2007. J Manag Care Pharm 13(8 Suppl A):4–7PubMed

American Cancer Society (2009) Cancer facts and figures 2009. Annual publication of the American Cancer Society, Atlanta, Georgia. http://www.cancer.org/downloads/STT/500809web.pdf

Nørgaard JM, Olesen LH, Hokland P (2004) Changing picture of cellular drug resistance in human leukemia. Crit Rev Oncol Hematol 50:39–49. doi:10.1016/S1040-8428(03)00173-2 PubMedCrossRef

Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217–229. doi:10.1016/S0163-7258(99)00073-X PubMedCrossRef

Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455(1):152–162. doi:10.1016/0005-2736(76)90160-7 PubMedCrossRef

Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9(1):105–127. doi:10.2217/14622416.9.1.105 PubMedCrossRef

Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M (2005) Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet 162:57–62. doi:10.1016/j.cancergencyto.2005.01.015 PubMedCrossRef

Kantarjian HM, Giles F, s-Cardama AQ, Cortes J (2007) Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13(4):1089–1097. doi:10.1158/1078-0432.CCR-06-2147 PubMedCrossRef

Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441–453. doi:10.1038/nrc2147 PubMedCrossRef

10.

Milojkovic D, Apperley J (2008) State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 20(1):112–121. doi:10.1097/CCO.0b013e3282f1fe8a PubMedCrossRef

11.

Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J, Andreasson C, Bua M, Olavarria E, Rahemtulla A, Dazzi F, Kanfer E, Goldman JM, Apperley JF (2005) Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19(4):507–512. doi:10.1038/sj.leu.2403664 PubMed

12.

Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368–2373PubMedCrossRef

13.

Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R (2002) Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug- resistant human CCRF-CEM leukemia. Blood Cell Mol Dis 28:160–168. doi:10.1006/bcmd.2002.0492 CrossRef

14.

Fernandes J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA, Gattass CR (2003) Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett 190(2):165–169. doi:10.1016/S0304-3835(02)00593-1 PubMedCrossRef

15.

Braga F, Ayres-Saraiva D, Gattass CR, Capella MA (2007) Oleanolic acid inhibits the activity of the multidrug resistance protein ABCC1 (MRP1) but not of the ABCB1 (P-glycoprotein): possible use in cancer chemotherapy. Cancer Lett 248(1):147–152. doi:10.1016/j.canlet.2006.06.008 PubMedCrossRef

16.

Rocha Gda G, Simões M, Lúcio KA, Oliveira RR, Coelho Kaplan MA, Gattass CR (2007) Natural triterpenoids from Cecropia lyratiloba are cytotoxic to both sensitive and multidrug resistant leukemia cell lines. Bioorg Med Chem 15(23):7355–7360. doi:10.1016/j.bmc.2007.07.020 PubMedCrossRef

17.

Delou JM, Capella MAM, Gattass CR (2009) Betulinic acid does not modulate the activity of P-gp/ABCB1or MRP1/ABCC1 in a non-tumoral renal cell line: possible utility in multidrug resistance cancer chemotherapy. Mol Med Rep 2:271–275. doi:10.3892/mmr_00000095

18.

Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA (2001) Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 73(1):57–69. doi:10.1590/S0001-37652001000100007 PubMedCrossRef

19.

Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O, Marie JP (2004) Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18(7):1246–1251. doi:10.1038/sj.leu.2403390 PubMedCrossRef

20.

Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45(3):321–334PubMed

21.

Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139(2):271–279PubMedCrossRef

22.

Neyfakh AA (1988) Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 174(1):168–176. doi:10.1016/0014-4827(88)90152-8 PubMedCrossRef

23.

Yusa K, Tsuruo T (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49(18):5002–5006PubMed

24.

Kujawski LA, Talpaz M (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 18(5–6):459–471. doi:10.1016/j.cytogfr.2007.06.015 PubMedCrossRef

25.

Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4:75–85. doi:10.1016/S1470-2045(03)00979-3 PubMedCrossRef

26.

Breccia M, Alimena G (2009) Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL. Curr Drug Targets 10(6):530–536PubMedCrossRef

27.

Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78(2):153–161. doi:10.1016/j.bcp.2009.04.002 PubMedCrossRef

28.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68(23):9809–9816. doi:10.1158/0008-5472.CAN-08-1008 PubMedCrossRef

29.

Lage H (2006) MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7(7):813–821. doi:10.1016/j.ics.2005.02.019 PubMedCrossRef

30.

Mimeault M, Hauke R, Batra SK (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83(5):673–691. doi:10.1038/sj.clpt.6100296 PubMedCrossRef

31.

Hall MD, Handley MD, Gottesman MM (2009) Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30(10):546–556. doi:10.1016/j.tips.2009.07.003 PubMedCrossRef

32.

Nobili S, Landini I, Giglioni B, Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7(7):861–879. doi:10.2174/138945006777709593 PubMedCrossRef

33.

American Society of Health-System Pharmacists (ASHP). http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book = meds. Accessed 5 January 2010

34.

Abd El-Ghaffar HA, Aladle DA, Farahat SE, El-Hady A (2006) P-glycoprotein (P-170) expression in acute leukemias. Hematology 11(1):35–41. doi:10.1080/10245330400026204 PubMedCrossRef

35.

Ugocsai K, Varga A, Molnár P, Antus S, Molnár J (2005) Effects of selected flavonoids and carotenoids on drug accumulation and apoptosis induction in multidrug-resistant colon cancer cells expressing MDR1/LRP. In Vivo 19(2):433–438PubMed

36.

Nguyen DM, Hussain M (2007) The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. J Bioenerg Biomembr 39(1):13–21. doi:10.1007/s10863-006-9055-9 PubMedCrossRef

37.

Liu XD, Sun H, Liu GT (2009) 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. Cancer Lett. Dec 2. [Epub ahead of print]. doi:10.1016/j.canlet.2009.11.001

38.

Volm M, Zintl F, Sauerbrey A (1996) Resistance-related proteins in initial and relapsed childhood acute lymphoblastic. leukemia. Int J Oncol 8:331–335. doi:10.1016/j.ejca.2005.09.017 PubMed

39.

Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3):1086–1099PubMed

40.

Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O (2005) MRP3, BCRP, and P-Glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11(21):7764–7772. doi:10.1158/1078-0432.CCR-04-1895 PubMedCrossRef

Title: 3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression
Authors: Gleice da Graça Rocha
Marisol Simões
Rodrigo Rodrigues Oliveira
Maria Auxiliadora Coelho Kaplan
Cerli Rocha Gattass
Publication date: 01-02-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9524-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2012

Antiangiogenic properties of an unusual benzo[k,l]xanthene lignan derived from CAPE (Caffeic Acid Phenethyl Ester)

Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab

Antitumor and antiangiogenic effects of GA-13315, a gibberellin derivative

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer